Scarica l'app Stockscreener
0.509
10.80%
-0.0616
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$0.5706
Aprire:
$0.54
Volume 24 ore:
1.84M
Relative Volume:
3.70
Capitalizzazione di mercato:
$21.76M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.0716
EPS:
-7.11
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
-10.43%
1M Prestazione:
-12.62%
6M Prestazione:
-74.16%
1 anno Prestazione:
-86.71%
Intervallo 1D:
$0.49
$0.5516
Intervallo di 1 settimana:
$0.49
$0.6114
Portata 52W:
$0.49
$4.17
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BTAI | 0.509 | 21.76M | 1.38M | -179.05M | -155.03M | -7.11 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Canada
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com
BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering - Benzinga
BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartz
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
500: Something went wrong - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
Earnings call: BioXcel Therapeutics reports Q3 2024 financials By Investing.com - Investing.com UK
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition - Investing.com India
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):